Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

BenzingaFeb 24 08:18 ET

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

GlobeNewswireFeb 24 08:15 ET

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

GlobeNewswireFeb 19 09:15 ET

Ignite Proteomics Publishes Study In British Journal of Cancer Titled "Functional Activation of the AKT–mTOR Signalling Axis in a Real-world Metastatic Breast Cancer Cohort"

BenzingaFeb 10 09:17 ET

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

GlobeNewswireFeb 10 09:15 ET

US Stocks Mixed; General Dynamics Earnings Top Views

BenzingaJan 29 10:10 ET